Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme

Diabetes, Obesity and Metabolism

Volumn 18, Issue 1, 2016, Pages 49-55

  Dungan, K M ^a   Raz, I ^b   Skrivanek, Z ^c   Sealls, W ^c   Fahrbach, J L ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Composite endpoint; Dulaglutide; GLP 1 analogue

Indexed keywords

DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; HEMOGLOBIN A1C PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PEPTIDE; VENOM;

ADD ON THERAPY; ADULT; AMERICAN INDIAN; ARTICLE; ASIAN; BLACK PERSON; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATIVE HAWAIIAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; TREATMENT DURATION; WEIGHT GAIN; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME; VENOMS; WEIGHT GAIN;

EID: 84955172764     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12575     Document Type: Article

References (22)

1. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
3. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 2011; 27(Suppl. 3): 13-20.
4. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007; 9: 799-812.
5. Bennett WL, Maruthur NM, Singh S etal. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
6. Garber AJ. Hypoglycaemia: a therapeutic concern in type 2 diabetes. Lancet 2012; 379: 2215-2216.
7. Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012; 14: 77-82.
8. Tong BC, Huber JC, Ascheim DD etal. Weighting composite endpoints in clinical trials: essential evidence for the heart team. Ann Thorac Surg 2012; 94: 1908-1913.
9. Stamler J, Neaton JD, Cohen JD etal. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J Am Heart Assoc 2012; 1: e003640.
10. Banerjee A, Fauchier L, Bernard-Brunet A, Clementy N, Lip GY. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2014; 111: 549-556.
11. Wittkop L, Smith C, Fox Z etal. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clin Trials 2010; 7: 19-35.
12. Myles PS, Devereaux PJ. Pros and cons of composite endpoints in anesthesia trials. Anesthesiology 2010; 113: 776-778.
13. Lavallee LT, Dahm P, Breau RH. Evidence-based urology in practice: composite endpoints. BJU Int 2010; 106: 610-612.
14. Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168-2176.
15. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
16. Dungan KM, Povedano ST, Forst T etal. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349-1357.
17. Wysham C, Blevins T, Arakaki R etal. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167.
18. Blonde L, Jendle J, Gross J etal. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015; 385: 2057-2066.
19. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015 Jun 18. [Epub ahead of print].
20. Bergenstal RM, Li Y, Porter TK, Weaver C, Han J. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c<7%, without weight gain or hypoglycaemia, over 52 weeks. Diabetes Obes Metab 2013; 15: 264-271.
21. Einarson TR, Garg M, Kaur V, Hemels ME. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab 2014; 16: 492-499.
22. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20-25.